Matinas BioPharma Holdings, Inc.
MTNB
$0.5571
-$0.0429-7.15%
AMEX
09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
---|---|---|---|---|---|
Revenue | -- | -- | -- | -100.00% | -- |
Total Other Revenue | -- | -- | -- | -- | -- |
Total Revenue | -- | -- | -- | -100.00% | -- |
Cost of Revenue | -32.05% | -5.28% | -13.20% | -5.22% | -11.11% |
Gross Profit | 32.05% | 5.28% | -19.90% | -30.71% | -24.62% |
SG&A Expenses | -24.55% | -5.08% | -9.44% | -16.97% | 0.75% |
Depreciation & Amortization | -- | -- | -- | -- | -- |
Other Operating Expenses | -- | -- | -- | -- | -- |
Total Operating Expenses | -28.58% | -5.20% | -11.67% | -10.03% | -5.99% |
Operating Income | 28.58% | 5.20% | -5.66% | -7.43% | -12.30% |
Income Before Tax | 29.40% | 5.63% | -5.64% | -46.23% | -10.86% |
Income Tax Expenses | -- | -- | -- | -- | -- |
Earnings from Continuing Operations | 29.40% | 5.63% | -5.64% | -46.23% | -10.86% |
Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
Minority Interest in Earnings | -- | -- | -- | -- | -- |
Net Income | 29.40% | 5.63% | -5.64% | -46.23% | -10.86% |
EBIT | 28.58% | 5.20% | -5.66% | -7.43% | -12.30% |
EBITDA | 28.92% | 5.18% | -5.79% | -7.54% | -12.36% |
EPS Basic | 39.10% | 17.77% | -5.60% | -45.01% | -10.86% |
Normalized Basic EPS | 39.10% | 17.77% | -5.59% | -45.00% | -10.86% |
EPS Diluted | 39.10% | 17.77% | -5.60% | -45.01% | -10.86% |
Normalized Diluted EPS | 39.10% | 17.77% | -5.59% | -45.00% | -10.86% |
Average Basic Shares Outstanding | 15.94% | 14.77% | 0.04% | 0.84% | 0.00% |
Average Diluted Shares Outstanding | 15.94% | 14.77% | 0.04% | 0.84% | 0.00% |
Dividend Per Share | -- | -- | -- | -- | -- |
Payout Ratio | -- | -- | -- | -- | -- |